1378391-45-7 Usage
Uses
Different sources of media describe the Uses of 1378391-45-7 differently. You can refer to the following data:
1. Velpatasvir S, R Isomer (Imidazole) BOC acts as a reagent in the preparation of peptide analog as antiviral agents, preparation of condensed pentacyclic imidazole derivatives as antiviral compounds.
2. Intermediates of Velpatasvir can be used as organic synthesis intermediates and pharmaceutical intermediates, mainly for the synthesis of API Velpatasvir.
Synthesis
tot-Butyl (2S,4S)-2-[5-(2-{(2S,5S)-l-[N-(methoxycarbonyl)-L-valyl]-5-methylpyrrolidin-2-yl}- l,ll-dihydroisochromeno[4',3':6,7]naphtho[l,2-d]imidazol-9-yl)-lH-imidazol-2-yl]-4- (methoxymethyl)pyrrolidine-l-carboxylate tert-Butyl (2S,4S)-2-[5-(2- {(2S,5S)-l-[N-(methoxycarbonyl)-L-valyl]-5-methylpyrrolidin-2- yl} -l ,4,5,l l-tetrahydroisochromeno[4',3':6,7]naphtho[l,2-d]imidazol-9-yl)-lH-imidazol-2-yl]-4- (methoxymethyl)pyrrolidine-l-carboxylate (8.33 g, 1.049 mmol) was suspended in DCM and activated Mn02 (55.0 g, 630 mmol) was added in a single portion. After 13 h, MeOH (200 mL) was added and the slurry was filtered over celite. The filter cake was washed with MeOH (600 mL) and the filtrate was concentrated under reduced pressure. The crude material was purified by silica column chromatography (0% to 45% MeOH/EtOAc) to afford tert-butyl (2S,4S)-2-[5-(2- {(2S,5S)-l-[N- (methoxycarbonyl)-L-valyl] -5 -methylpyrrolidin-2-yl} -1,11- dihydroisochromeno[4',3':6,7]naphtho[l,2-d]imidazol-9-yl)-lH-imidazol-2-yl]-4- (methoxymethyl)pyrrolidine-l-carboxylate (4.85 g, 58%).
Check Digit Verification of cas no
The CAS Registry Mumber 1378391-45-7 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,3,7,8,3,9 and 1 respectively; the second part has 2 digits, 4 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 1378391-45:
(9*1)+(8*3)+(7*7)+(6*8)+(5*3)+(4*9)+(3*1)+(2*4)+(1*5)=197
197 % 10 = 7
So 1378391-45-7 is a valid CAS Registry Number.
1378391-45-7Relevant articles and documents
Preparation method of velpatasvir intermediate
-
Paragraph 0025-0036, (2020/05/01)
The invention discloses a preparation method of a velpatasvir intermediate. The method comprises the following steps: dissolving a compound 1 in an organic solvent, adding ammonium acetate and a catalyst, and completing cyclization and oxidation reactions in one step. The method has the advantages of reaction step shortening, simplicity in post-treatment, few three wastes, low production cost, suitableness for industrial production, and substantial social and economic benefits.
Compound used for inhibiting hepatitis C virus, and pharmaceutical applications thereof
-
, (2018/04/01)
The invention relates to a compound which is represented by formula I, is used for inhibiting hepatitis C virus, and possesses excellent bioavailability, and a nontoxic pharmaceutically acceptable salt thereof. The compound possesses extremely high inhibition effect on HCV of all genotypes. In the formula I, R is used for representing hydrogen atom, glycyl, L-alanyl, L-leucyl, L-valyl, or L-isoleucyl.
ANTIVIRAL COMPOUNDS
-
, (2013/12/03)
The disclosure is related to anti-viral compounds, compositions containing such compounds, and therapeutic methods that include the administration of such compounds, as well as to processes and intermediates useful for preparing such compounds.
